Table 2.
Treatment-emergent adverse events (TEAEs) identified as likely or possibly due to pazopanib in the 13-patient cohort
| TEAE | CTCAE v 5.0 grade* | No. of patients (%) |
|---|---|---|
| Hypertension | 2 | 4 (31%) |
| Lymphocytopenia | 1 | 2 (15%) |
| 2 | 1 (8%) | |
| Fatigue | 1 | 3 (23%) |
| Headache | 1 | 2 (15%) |
| Dyspepsia | 1 | 2 (15%) |
| Hypothyroidism† | 2 | 2 (15%) |
| Dysgeusia | 1 | 1 (8%) |
| Hypophosphatemia | 2 | 1 (8%) |
| Benign migratory glossitis (geographic tongue) | 1 | 1 (8%) |
TEAEs observed in 3 patients excluded from the primary analysis are detailed in the Supplementary Appendix
*Where multiple patients had a TEAE and one grade is given, this grade applied to all patients with that TEAE
†Both patients developing hypothyroidism as a TEAE had pre-existing hypothyroidism, with worsening requiring uptitration of thyroid replacement after initiating pazopanib